Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OMX-4.80
- Development stage
- Unknown
- Lead developer
- Omniox
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
**OMX-4.80** is an engineered H-NOX domain protein serving as an oxygen carrier designed to preferentially penetrate and oxygenate hypoxic tumor tissues, enhancing the efficacy of radiotherapy (RT). Developed by Omniox, Inc., it selectively releases oxygen in low-oxygen microenvironments, reducing tumor hypoxia without causing cardiovascular, renal, or hypertensive toxicities associated with hemoglobin-based carriers. Preclinical studies in mouse glioblastoma models and other hypoxic cancers demonstrate tumor growth delay and survival benefits when combined with RT, attributed to its ability to cross the blood-tumor barrier and persist in tumors.[1][5]
- Other names
- OMX
Beyond the preview
Go deeper on OMX-4.80.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMX-4.80.